How Regulatory Momentum and Precision Therapies Are Accelerating the Global Immunotherapy Market Growth at 11.5% CAGR

The global immunotherapy market was valued at $216.5 billion in 2024 and is projected to reach $710.3 billion by 2035, growing at a CAGR of 11.5% during the forecast period (2025–2035). The global immunotherapy market is witnessing strong growth driven by the rising incidence of cancer and the increasing demand for more effective, durable, and targeted treatment options. Immunotherapies such as checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines are gaining widespread adoption due to their ability to improve survival outcomes and reduce relapse rates.

Browse the full report description of “Immunotherapy Market Size, Share & Trends Analysis Report by Type (Monoclonal Antibodies, Cancer Vaccines, Autoimmune Checkpoint Inhibitors, Interleukins and Interferons (Cytokines), and Others) by Application (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others) and by End User (Hospitals, Diagnostic Centers, and Others) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/immunotherapy-market

At the same time, technological advancements in genomics, biomarkers, and personalized medicine are enabling more precise patient stratification and therapy selection. Supportive regulatory approvals across major markets are accelerating commercialization, expanding treatment indications, and strengthening global market penetration.

Key Developments Highlighting Market Growth

• 2024: Regulatory authorities in the U.S., Europe, and Asia approved multiple new immunotherapy drugs and expanded indications for existing checkpoint inhibitors, supporting rapid market expansion.
• 2024: Advances in personalized medicine, including biomarker-driven patient selection, improved clinical response rates and optimized treatment outcomes in immunotherapy trials.
• 2025: Leading biopharmaceutical companies increased investments in next-generation immunotherapies, including cell-based and combination therapies, reflecting strong confidence in long-term market growth.

Innovation, Partnerships, and Pipeline Expansion

Industry players are focusing on expanding immunotherapy pipelines through continuous R&D, strategic collaborations, and combination-therapy development. Pharmaceutical companies are also leveraging fast-track regulatory pathways and real-world evidence to speed up approvals and broaden access to immunotherapy across oncology and autoimmune indications.

Recent Strategic Developments in the Global Immunotherapy Market

• In 2025, Merck & Co., Inc. launched its next-generation immunotherapy treatment featuring enhanced efficacy in multiple cancer types and a favourable safety profile, reinforcing its position in precision immuno-oncology.
• In 2024, Bristol-Myers Squibb completed the acquisition of a biotech company specializing in novel immune checkpoint inhibitors, strengthening its immunotherapy pipeline with new targeted agents.
• In 2025, AstraZeneca plc announced a strategic collaboration with a leading research institute to co-develop cutting-edge CAR-T and T-cell receptor therapies, aimed at expanding treatment options for hard-to-treat cancers.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Type
• Application
• End-User

• Competitive Landscape – AbbVie, Bristol-Myers Squibb (BMS), Hoffmann-La Roche Ltd., Merck & Co. and Novartis AG.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Immunotherapy Market Report Segment

By Type

• Monoclonal Antibodies
• Cancer Vaccines
• Autoimmune Checkpoint Inhibitors
• Interleukins and Interferons (Cytokines)
• Others

By Application

• Cancer
• Autoimmune and Inflammatory Diseases
• Infectious Diseases
• Other Application

By End-User

• Hospitals
• Diagnostic Centers
• Others

Global Immunotherapy Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/immunotherapy-market